BioSpace News Archive

- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF - Raised approximately $349 million in gross proceeds, which is expected to fund operations for at least two years

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF in its first quarterly rebalance of holdings.

Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells.

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform is

CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.

At the Experimental Nuclear Magnetic Resonance Conference 2021 (ENC), Bruker Corporation (Nasdaq: BRKR) announces that the Forschungszentrum Juelich (FZJ), Germany has expanded its research into functional structural biology in neurodegenerative diseases with the addition of a 1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometer

— PRIME Designation to Facilitate Greater EMA Collaboration for Development and Potential Accelerated Regulatory Review in Europe — — LAD-I Program Now Holds All Available Accelerated Regulatory Designations in the U.S. and EU —

Foundation Medicine, Inc. today announced the appointment of Brian Alexander, M.D., M.P.H., as chief executive officer, effective April 6, 2021. Dr. Alexander previously served as Foundation Medicine’s chief medical officer since 2019 and brings with him years of experience as a radiation oncologist at Dana-Farber/Brigham

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States

Meso Scale Diagnostics, LLC. announced the commercial release of its V-PLEX® Serology Panels for SARS-CoV-2 variants.